Cargando…

Detecting Breast Cancer with a Dual-Modality Device

Although mammography has been the gold standard for the early detection of breast cancer, if a woman has dense breast tissue, a false negative diagnosis may occur. Breast ultrasound, whether hand-held or automated, is a useful adjunct to mammography but adds extra time and cost. The primary aim was...

Descripción completa

Detalles Bibliográficos
Autores principales: Padia, Kamila, Douglas, Tania S., Cairncross, Lydia L., Baasch, Roland V., Vaughan, Christopher L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5373026/
https://www.ncbi.nlm.nih.gov/pubmed/28335472
http://dx.doi.org/10.3390/diagnostics7010017
_version_ 1782518740528660480
author Padia, Kamila
Douglas, Tania S.
Cairncross, Lydia L.
Baasch, Roland V.
Vaughan, Christopher L.
author_facet Padia, Kamila
Douglas, Tania S.
Cairncross, Lydia L.
Baasch, Roland V.
Vaughan, Christopher L.
author_sort Padia, Kamila
collection PubMed
description Although mammography has been the gold standard for the early detection of breast cancer, if a woman has dense breast tissue, a false negative diagnosis may occur. Breast ultrasound, whether hand-held or automated, is a useful adjunct to mammography but adds extra time and cost. The primary aim was to demonstrate that our second-generation Aceso system, which combines full-field digital mammography (FFDM) and automated breast ultrasound (ABUS) in a single platform, is able to produce improved quality images that provide clinically meaningful results. Aceso was first tested using two industry standards: a Contrast Detail Mammography (CDMAM) phantom to assess the FFDM images, and the CIRS 054GS phantom to evaluate the ABUS images. In addition, 25 women participated in a clinical trial: 14 were healthy volunteers, while 11 were patients referred by the breast clinic at Groote Schuur Hospital. The CDMAM phantom results showed the FFDM results were better than the European Reference (EUREF) standard of “acceptable” and were approaching “achievable”. The ABUS results showed a lateral and axial spatial resolution of 0.5 mm and an adequate depth penetration of 80 mm. Our second-generation Aceso system, with its improved quality of clinical FFDM and ABUS images, has demonstrated its potential for the early detection of breast cancer in a busy clinic.
format Online
Article
Text
id pubmed-5373026
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-53730262017-04-05 Detecting Breast Cancer with a Dual-Modality Device Padia, Kamila Douglas, Tania S. Cairncross, Lydia L. Baasch, Roland V. Vaughan, Christopher L. Diagnostics (Basel) Article Although mammography has been the gold standard for the early detection of breast cancer, if a woman has dense breast tissue, a false negative diagnosis may occur. Breast ultrasound, whether hand-held or automated, is a useful adjunct to mammography but adds extra time and cost. The primary aim was to demonstrate that our second-generation Aceso system, which combines full-field digital mammography (FFDM) and automated breast ultrasound (ABUS) in a single platform, is able to produce improved quality images that provide clinically meaningful results. Aceso was first tested using two industry standards: a Contrast Detail Mammography (CDMAM) phantom to assess the FFDM images, and the CIRS 054GS phantom to evaluate the ABUS images. In addition, 25 women participated in a clinical trial: 14 were healthy volunteers, while 11 were patients referred by the breast clinic at Groote Schuur Hospital. The CDMAM phantom results showed the FFDM results were better than the European Reference (EUREF) standard of “acceptable” and were approaching “achievable”. The ABUS results showed a lateral and axial spatial resolution of 0.5 mm and an adequate depth penetration of 80 mm. Our second-generation Aceso system, with its improved quality of clinical FFDM and ABUS images, has demonstrated its potential for the early detection of breast cancer in a busy clinic. MDPI 2017-03-18 /pmc/articles/PMC5373026/ /pubmed/28335472 http://dx.doi.org/10.3390/diagnostics7010017 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Padia, Kamila
Douglas, Tania S.
Cairncross, Lydia L.
Baasch, Roland V.
Vaughan, Christopher L.
Detecting Breast Cancer with a Dual-Modality Device
title Detecting Breast Cancer with a Dual-Modality Device
title_full Detecting Breast Cancer with a Dual-Modality Device
title_fullStr Detecting Breast Cancer with a Dual-Modality Device
title_full_unstemmed Detecting Breast Cancer with a Dual-Modality Device
title_short Detecting Breast Cancer with a Dual-Modality Device
title_sort detecting breast cancer with a dual-modality device
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5373026/
https://www.ncbi.nlm.nih.gov/pubmed/28335472
http://dx.doi.org/10.3390/diagnostics7010017
work_keys_str_mv AT padiakamila detectingbreastcancerwithadualmodalitydevice
AT douglastanias detectingbreastcancerwithadualmodalitydevice
AT cairncrosslydial detectingbreastcancerwithadualmodalitydevice
AT baaschrolandv detectingbreastcancerwithadualmodalitydevice
AT vaughanchristopherl detectingbreastcancerwithadualmodalitydevice